Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

777 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-16

Study Completion Date

2018-09-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice

NCT01652690

Osteoporosis, Postmenopausal

COMPLETED

Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis

NCT01668589

Postmenopausal Osteoporosis

COMPLETED

Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

NCT02732210

Osteoporosis, Age-Related

COMPLETED

A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

NCT04757376

Postmenopausal Women With Osteoporosis

COMPLETED PHASE3

Continuation of Anti-osteoporotic Treatment 1 Year After Initial Administration

NCT06024148

Osteoporosis Fracture

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, observational and non-interventional study in PMO patients who receive Prolia® (60 mg subcutaneous \[SC\]) in France. Patients in the study will be enrolled in 2 waves, each targeting specific aspects of the overall study objectives. The first wave will enroll approximately 500 patients who will be followed for approximately 30 months from the first injection. Patients enrolled in this wave will provide descriptive data on persistence to Prolia® as well as a description of the characteristics of patients being prescribed Prolia®, information regarding Prolia® prescription and administration, procedures pertaining to Prolia® and safety.

The second wave will enroll approximately 250 patients and will only provide a cross-sectional description of the characteristics of patients being prescribed Prolia.

Around 2000 specialists in rheumatology and 9000 general practitioners will be randomly selected from a list of rheumatologists whether in hospital or private practice nationwide and a list of general practitioners managing patients with osteoporosis.

In all, 300 physicians initially interested to participate are expected, from which about 180 physicians will be qualified to participate. One-hundred and ten physicians will be initiated.

There are no procedures or changes to the routine clinical management of patients participating in the study. Baseline characteristics will be described for patients enrolling in both waves 1 and 2. Patients enrolling in wave 1 will be followed for approximately 30 months from the date of first injection in the study. It is anticipated that patients will return to the site. Clinical information obtained for routine clinical practice will be recorded where available, including Prolia administration, previous and current therapies, medical history (including fracture), ADRs, SADRs and co-morbidities.The study is descriptive in nature, and no formal hypothesis will be tested. In general, data summaries will be presented by wave and by subgroups of interest.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Menopausal Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

wave 1

postmenopausal women with osteoporosis treated with Prolia

AMG 162 - Prolia

Intervention Type DRUG

500 patients

wave 2

postmenopausal women with osteoporosis treated with Prolia

AMG 162 - Prolia

Intervention Type DRUG

250 patients, one year later

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMG 162 - Prolia

500 patients

Intervention Type DRUG

AMG 162 - Prolia

250 patients, one year later

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

denosumab denosumab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* post menopausal osteoporosis women in whom a decision has been made to treat with Prolia in the last 4 weeks
* received their first prescription of Prolia in the last 4 weeks
* patient has provided informed consent before enrolling in the study